CN103649336A - 用于个体化治疗管理的疾病活动性表征方法 - Google Patents

用于个体化治疗管理的疾病活动性表征方法 Download PDF

Info

Publication number
CN103649336A
CN103649336A CN201280034138.2A CN201280034138A CN103649336A CN 103649336 A CN103649336 A CN 103649336A CN 201280034138 A CN201280034138 A CN 201280034138A CN 103649336 A CN103649336 A CN 103649336A
Authority
CN
China
Prior art keywords
tnf
mucous membrane
therapy
ati
markers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280034138.2A
Other languages
English (en)
Chinese (zh)
Inventor
S·辛格
N·霍
S·洛克腾
S·豪恩施泰因
L·奥尔穆德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Societe des Produits Nestle SA
Original Assignee
Societe dAssistance Technique pour Produits Nestle SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Societe dAssistance Technique pour Produits Nestle SA filed Critical Societe dAssistance Technique pour Produits Nestle SA
Priority to CN201910821596.4A priority Critical patent/CN110544517A/zh
Publication of CN103649336A publication Critical patent/CN103649336A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/563—Immunoassay; Biospecific binding assay; Materials therefor involving antibody fragments
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN201280034138.2A 2011-05-10 2012-05-10 用于个体化治疗管理的疾病活动性表征方法 Pending CN103649336A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910821596.4A CN110544517A (zh) 2011-05-10 2012-05-10 用于个体化治疗管理的疾病活动性表征方法

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201161484607P 2011-05-10 2011-05-10
US61/484,607 2011-05-10
US201161505026P 2011-07-06 2011-07-06
US61/505,026 2011-07-06
US201161553909P 2011-10-31 2011-10-31
US61/553,909 2011-10-31
US201161566509P 2011-12-02 2011-12-02
US61/566,509 2011-12-02
US201261636575P 2012-04-20 2012-04-20
US61/636,575 2012-04-20
PCT/US2012/037375 WO2012154987A1 (en) 2011-05-10 2012-05-10 Methods of disease activity profiling for personalized therapy management

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201910821596.4A Division CN110544517A (zh) 2011-05-10 2012-05-10 用于个体化治疗管理的疾病活动性表征方法

Publications (1)

Publication Number Publication Date
CN103649336A true CN103649336A (zh) 2014-03-19

Family

ID=46147068

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201280034138.2A Pending CN103649336A (zh) 2011-05-10 2012-05-10 用于个体化治疗管理的疾病活动性表征方法
CN201910821596.4A Pending CN110544517A (zh) 2011-05-10 2012-05-10 用于个体化治疗管理的疾病活动性表征方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201910821596.4A Pending CN110544517A (zh) 2011-05-10 2012-05-10 用于个体化治疗管理的疾病活动性表征方法

Country Status (14)

Country Link
US (3) US10086072B2 (enExample)
EP (1) EP2707504A1 (enExample)
JP (3) JP2014517279A (enExample)
KR (1) KR20140032424A (enExample)
CN (2) CN103649336A (enExample)
AU (1) AU2012253422B2 (enExample)
BR (1) BR112013028808A2 (enExample)
CA (1) CA2839792A1 (enExample)
IL (1) IL229120B (enExample)
MX (2) MX362132B (enExample)
RU (1) RU2013154566A (enExample)
SG (1) SG194710A1 (enExample)
WO (1) WO2012154987A1 (enExample)
ZA (1) ZA201309258B (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105190314A (zh) * 2013-01-21 2015-12-23 阿布维公司 用于炎性疾病的抗-tnf和抗-il17联合疗法生物标志物
CN109998488A (zh) * 2019-04-13 2019-07-12 中国医学科学院北京协和医院 克罗恩病和肠道溃疡型淋巴瘤的鉴别模型及构建方法
CN114859060A (zh) * 2022-05-06 2022-08-05 广州市胸科医院 一种细胞因子组及其应用

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110229471A1 (en) 2008-11-26 2011-09-22 Cedars-Sinai Medical Center Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
AU2012253422B2 (en) 2011-05-10 2015-08-13 Société des Produits Nestlé S.A. Methods of disease activity profiling for personalized therapy management
ES2751391T3 (es) 2013-03-21 2020-03-31 Univ Michigan Regents Procedimientos de tratamiento de trastornos metabólicos
EP4105236A1 (en) 2013-07-19 2022-12-21 Cedars-Sinai Medical Center Anti-tl1a (tnfsf15) antibody for treatment of inflammatory bowel disease
WO2015110989A1 (en) * 2014-01-23 2015-07-30 Nestec S.A. Biomarker panel for assessment of mucosal healing
US10846371B2 (en) * 2014-04-10 2020-11-24 Yissum Research Development Company of the Hebrew University of Jerusalm Ltd. Methods and kits for determining a personalized treatment regimen for a subject suffering from a pathologic disorder
WO2015166461A1 (en) 2014-05-01 2015-11-05 Nestec S.A. Methods of selecting treatment regimen using tnf alpha and anti-tnf alpha drug levels
WO2015169966A2 (en) * 2014-05-09 2015-11-12 Nogra Pharma Limited Methods for treating inflammatory bowel disease
WO2015175926A1 (en) * 2014-05-15 2015-11-19 Children's Medical Center Corporation Systems and methods for identifying neurobiological biomarkers using eeg
MX2017004742A (es) 2014-10-20 2017-07-20 Nestec Sa Métodos para la predicción de niveles de farmacos anti-tnf alfa y formación de autoanticuerpos.
WO2016088068A1 (en) 2014-12-02 2016-06-09 Nestec S.A. Methods for establishing a vedolizumab dosing regimen to treat patients with irritable bowel disease
EP3227683B1 (en) 2014-12-05 2019-04-24 Nestec S.A. Indirect homogeneous mobility shift assays for the detection of biologics in patient samples
US20180224464A1 (en) * 2015-06-09 2018-08-09 Osaka University Method of predicting and determining therapeutic effect on rheumatoid arthritis due to biological formulation
WO2017027709A1 (en) 2015-08-11 2017-02-16 Cognoa, Inc. Methods and apparatus to determine developmental progress with artificial intelligence and user input
US11972336B2 (en) 2015-12-18 2024-04-30 Cognoa, Inc. Machine learning platform and system for data analysis
JP7082945B2 (ja) 2016-03-17 2022-06-09 シーダーズ―シナイ メディカル センター Ｒｎａｓｅｔ２により炎症性腸疾患を診断する方法
JP2019514939A (ja) * 2016-04-26 2019-06-06 クー バイオロジックス インコーポレイテッドＱｕ Ｂｉｏｌｏｇｉｃｓ Ｉｎｃ． 標的組織における自然免疫応答の治療的誘発
CN109476698B (zh) 2016-05-20 2023-10-17 西达-赛奈医疗中心 基于基因的炎性肠病诊断
GB201611738D0 (en) 2016-07-05 2016-08-17 Cambridge Entpr Ltd Biomarkers for inflammatory bowel disease
EP3529379B1 (en) 2016-10-24 2022-05-18 Nederlandse Organisatie voor toegepast- natuurwetenschappelijk onderzoek TNO System and method for implementing meal selection based on vitals, genotype, and phenotype
WO2018085937A1 (en) * 2016-11-14 2018-05-17 Qu Biologics Inc. Managing site specific ibd immunotherapies
CN110192252A (zh) 2016-11-14 2019-08-30 科格诺亚公司 用于评估发育状况并提供覆盖度和可靠性控制的方法和装置
US20220254461A1 (en) * 2017-02-09 2022-08-11 Cognoa, Inc. Machine learning algorithms for data analysis and classification
EP3580700A4 (en) * 2017-02-09 2020-11-18 Cognoa, Inc. PLATFORM AND SYSTEM FOR DIGITAL PERSONALIZED MEDICINE
CN111094984A (zh) 2017-05-31 2020-05-01 普罗米修斯生物科学公司 克罗恩氏病患者的粘膜愈合评估方法
KR20200069333A (ko) 2017-10-10 2020-06-16 프로메테우스 바이오사이언시즈, 인크. 베돌리주맙 치료를 모니터링하는 방법
US11270800B1 (en) * 2017-11-09 2022-03-08 Aptima, Inc. Specialized health care system for selecting treatment paths
KR102424222B1 (ko) * 2017-11-13 2022-07-21 더 멀티플 마이얼로머 리서치 파운데이션, 인크. 통합된, 분자, 체학, 면역요법, 대사, 후성적, 및 임상 데이터베이스
WO2019178546A1 (en) 2018-03-16 2019-09-19 Scipher Medicine Corporation Methods and systems for predicting response to anti-tnf therapies
JP2020028278A (ja) * 2018-08-24 2020-02-27 国立大学法人九州大学 被検体に生じるイベントを予測するための判別器の生成方法、及び前記判別器を用いた被検体の層別化方法
MX2021011493A (es) 2019-03-22 2022-01-04 Cognoa Inc Métodos y dispositivos de terapia digital personalizados.
AU2020275413A1 (en) 2019-05-14 2021-12-23 Cedars-Sinai Medical Center TL1A patient selection methods, systems, and devices
CA3145237A1 (en) * 2019-06-27 2020-12-30 Scipher Medicine Corporation Developing classifiers for stratifying patients
WO2021097074A1 (en) * 2019-11-13 2021-05-20 New York University Intestinal organoid co-culture systems and methods for treating or preventing a disease or disorder associated with immune response-mediated tissue injury
US20230352174A1 (en) * 2020-12-29 2023-11-02 Kpn Innovations, Llc. Systems and methods for generating a parasitic infection program
US20240395384A1 (en) * 2021-09-30 2024-11-28 Prometheus Laboratories Inc. Patient centric precision model for anti-tnf therapy
WO2023064437A1 (en) * 2021-10-15 2023-04-20 The Trustees Of Indiana University Methods for detecting fracture-related infection (fri)
US20240120050A1 (en) * 2022-10-07 2024-04-11 Insight Direct Usa, Inc. Machine learning method for predicting a health outcome of a patient using video and audio analytics
US11887720B1 (en) * 2023-01-23 2024-01-30 Kpn Innovations, Llc Apparatus and method for using a feedback loop to optimize meals
US12362058B2 (en) 2023-01-23 2025-07-15 Kpn Innovations, Llc. Apparatus and method for using a feedback loop to optimize meals
WO2025250715A1 (en) * 2024-05-30 2025-12-04 Arizona Board Of Regents On Behalf Of Arizona State University Methods and related aspects for rapid cytokine detection for inflammatory disease diagnosis

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110045476A1 (en) * 2009-04-14 2011-02-24 Prometheus Laboratories Inc. Inflammatory bowel disease prognostics

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1262493A1 (en) 1992-10-29 2002-12-04 Bayer Corporation Diagnostic assay for latent matrix metalloproteinase no. 9
DK0615129T3 (da) 1993-03-10 2000-08-07 Cedars Sinai Medical Center Fremgangsmåder til selektiv påvisning af perinukleært anti-neutrophilt cytoplasmatisk antistof fra ulcerativ colitis eller
US5830675A (en) 1993-03-10 1998-11-03 Cedars-Sinai Medical Center Methods for selectively detecting perinuclear anti-neutrophil cytoplasmic antibody of ulcerative colitis, primary sclerosing cholangitis, or type 1 autoimmune hepatitis
US20020025553A1 (en) 1996-01-04 2002-02-28 Ying-Fei Wei Transforming growth factor alpha HIII
US6074835A (en) 1996-04-12 2000-06-13 Regents Of The Univ. Of California Diagnosis, prevention and treatment of ulcerative colitis, and clinical subtypes thereof, using histone H1
US6033864A (en) 1996-04-12 2000-03-07 The Regents Of The University Of California Diagnosis, prevention and treatment of ulcerative colitis, and clinical subtypes thereof, using microbial UC pANCA antigens
US6319899B1 (en) 1997-09-17 2001-11-20 The Nemours Foundation Method and composition for the treatment of inflammatory bowel disease
US6218129B1 (en) 1998-05-15 2001-04-17 Prometheus Laboratories, Inc. Inflammatory bowel disease first step assay system
RU2141332C1 (ru) 1998-06-24 1999-11-20 Научно-исследовательский институт фармакологии Томского научного центра РАМН Противоязвенное средство и способ его получения
US6406862B1 (en) 1998-10-06 2002-06-18 The United States Of America As Represented By The Secretary Of The Army Dip-stick assay for C-reactive protein
US6309643B1 (en) 1999-04-30 2001-10-30 The Regents Of The University Of California IBD-associated microbial antigens and methods of using same
FR2802536B1 (fr) 1999-11-23 2003-06-13 Chru Lille Oligomannosides de synthese, leur preparation et leur utilisation a la detection d'anticorps et a la prevention d'infections
FR2806739B1 (fr) 2000-03-27 2005-02-18 Fond Jean Dausset Ceph Genes impliques dans les maladies inflammatoires de l'intestin et leur utilisation
US6838250B2 (en) 2000-03-31 2005-01-04 Ortho-Clinical Diagnostics, Inc. Immunoassay for C-reactive protein
US7138237B1 (en) 2000-05-19 2006-11-21 Cedars-Sinai Medical Center Diagnosis, prevention and treatment of Crohn's disease using the OmpC antigen
AU1169702A (en) 2000-10-13 2002-04-22 Childrens Medical Center Non-invasive enzyme screen for tissue remodelling-associated conditions
WO2002036773A2 (en) 2000-10-30 2002-05-10 Regents Of The University Of Michigan Nod2 nucleic acids and proteins
AU4341502A (en) 2000-10-30 2002-06-11 Univ Michigan Nod2 nucleic acids and proteins
EP1340078B1 (en) 2000-11-14 2009-05-27 Techlab, Inc. Method for differentiating irritable bowel syndrome from inflammatory bowel disease (ibd) and for monitoring persons with ibd using total endogenous lactoferrin as a marker
US20050154536A1 (en) 2001-08-30 2005-07-14 The University Of Pittsburgh - Of The Commonwealth System Of Higher Education Two-part drug discovery system
EP1432984A4 (en) 2001-08-30 2009-01-14 Univ Pittsburgh ALGORITHM FOR ASSESSING THE RESULTS OF INFLAMMATION FOR INJURY OR INFECTION
AU2002365279B2 (en) 2001-12-17 2009-08-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of inflammatory bowel disease
US20040053263A1 (en) 2002-08-30 2004-03-18 Abreu Maria T. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease
CA2502976C (en) 2002-10-25 2012-05-22 Techlab, Inc. Inflammatory bowel disease and irritable bowel syndrome ibd-first chek diagnostic panel
US20040197304A1 (en) 2003-04-01 2004-10-07 The Procter & Gamble Company And Alimentary Health, Ltd. Methods of determining efficacy of treatments of inflammatory diseases of the bowel
US7662569B2 (en) 2003-04-11 2010-02-16 Cedars-Sinai Medical Center Methods of assessing Crohn's disease patient phenotype by I2 serologic response
WO2005009339A2 (en) 2003-05-30 2005-02-03 Pathway Diagnostics Corporation, Inc. (a Delaware Corporation) Inflammatory bowel diseases
ATE490275T1 (de) 2003-06-23 2010-12-15 Genetics Inst Llc Antikörper gegen interleukin-22 und verwendungen dafür
EP1687447A4 (en) 2003-11-03 2008-04-02 Univ Duke METHOD FOR IDENTIFYING INDIVIDUALS IN THE HAZARD OF PERIOPERATIVE BLOODING, A KIDNEY PROBLEM OR A STROKE
MX350383B (es) 2004-01-09 2017-09-04 Pfizer Anticuerpos contra madcam.
FI119572B (fi) 2004-03-05 2008-12-31 Biohit Oyj Menetelmä vatsan limakalvon tilan ennustamiseksi
US20060019410A1 (en) 2004-07-21 2006-01-26 Qualyst, Inc. Apparatus, kits and methods for evaluating binding interactions, for detecting and quantifying binding molecules, and for sample preparation
EP1810198A1 (en) 2004-09-09 2007-07-25 Université de Liège Identification and use of biomarkers for the diagnosis and the prognosis of inflammatory diseases.
AR051444A1 (es) 2004-09-24 2007-01-17 Centocor Inc Proteinas derivadas de inmunoglobulina especifica de il-23p40, composiciones, epitopos, metodos y usos
US7462446B2 (en) 2005-03-18 2008-12-09 University Of Washington Magnetic nanoparticle compositions and methods
JP2009513645A (ja) 2005-10-26 2009-04-02 ノバルティス アクチエンゲゼルシャフト ＩＬ−１β化合物の新規使用
JP2009541338A (ja) 2006-06-19 2009-11-26 ワイス Ｉｌ−２２およびｉｌ−１７の調節方法
US20080085524A1 (en) * 2006-08-15 2008-04-10 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
RU2442171C2 (ru) 2006-09-21 2012-02-10 Промитьюс Лабораториз Инк. Чипы на основе антител для определения множественных трансдукторов сигналов в редких циркулирующих клетках
US8165819B2 (en) 2006-10-10 2012-04-24 The University of Pittsburgh—Of the Commonwealth System of Higher Education Modeling wound healing
WO2008095136A2 (en) 2007-01-31 2008-08-07 Henkin Robert I Methods for detection of biological substances
US20100255513A1 (en) 2007-03-30 2010-10-07 Denson Lee A Serological markers of inflammatory bowel disease phenotype and disease progression
GB2447865A (en) 2007-03-30 2008-10-01 Ethicon Inc Diagnostic markers of wound infection
WO2008147869A2 (en) * 2007-05-22 2008-12-04 Centocor, Inc. Markers and methods for assessing and treating crohn's disease and related disorders
AU2008276251B2 (en) 2007-07-13 2014-04-24 Nestec S.A. Drug selection for lung cancer therapy using antibody-based arrays
EP2602623B1 (en) 2008-02-25 2015-09-16 Nestec S.A. Mehtod for the detection of intracellular truncated receptors
JP5550633B2 (ja) 2008-03-26 2014-07-16 セラノス， インコーポレイテッド 臨床転帰を評価するための方法およびシステム
US20110059445A1 (en) * 2008-03-28 2011-03-10 Paul Rutgeerts Mucosal gene signatures
CA2734604A1 (en) * 2008-08-25 2010-04-22 Centocor Ortho Biotech Inc. Biomarkers for anti-tnf treatment in ulcerative colitis and related disorders
AU2009285644B2 (en) * 2008-08-29 2015-08-20 Janssen Biotech, Inc. Markers and methods for assessing and treating ulcerative colitis and related disorders using a 20 gene panel
US20120046197A1 (en) 2009-05-01 2012-02-23 Meso Scale Technologies, Llc Biomarkers of therapeutic responsiveness
EP2430443B1 (en) 2009-05-14 2018-06-27 Pierian Holdings, Inc. Biomarkers for determining sensitivity of breast cancer cells to her2-targeted therapy
AU2010266028B2 (en) 2009-06-25 2015-04-30 Société des Produits Nestlé S.A. Methods for diagnosing irritable bowel syndrome
EP2454598B1 (en) 2009-07-15 2017-03-22 DiaTech Holdings, Inc. Drug selection for gastric cancer therapy using antibody-based arrays
EA026401B1 (ru) 2009-09-02 2017-04-28 Новартис Аг Иммуногенные композиции, содержащие модуляторы активности tlr
AU2010306593B2 (en) * 2009-10-15 2015-09-10 Crescendo Bioscience, Inc. Biomarkers and methods for measuring and monitoring inflammatory disease activity
CA2777934A1 (en) 2009-10-20 2011-04-28 Prometheus Laboratories Inc. Proximity-mediated assays for detecting oncogenic fusion proteins
NZ599456A (en) 2009-10-26 2014-06-27 Nestec Sa Assays for the detection of anti-tnf drugs and autoantibodies
AU2010324735A1 (en) 2009-11-25 2012-07-12 Nestec S.A. Novel genomic biomarkers for irritable bowel syndrome diagnosis
EP2539470B1 (en) 2010-02-24 2017-02-22 The Board of Trustees of The Leland Stanford Junior University Methods for autoimmune disease diagnosis, prognosis, and treatment
MX2012014096A (es) 2010-06-04 2013-04-19 Nestec Sa Métodos para mejorar el diagnóstico de enfermedad intestinal inflamatoria.
US20140148350A1 (en) 2010-08-18 2014-05-29 David Spetzler Circulating biomarkers for disease
SG10201510086VA (en) 2010-12-23 2016-01-28 Nestec Sa Drug selection for malignant cancer therapy using antibody-based arrays
EP2908132B8 (en) 2011-03-02 2019-06-12 Nestec S.A. Prediction of drug sensitivity of lung tumors based on molecular and genetic signatures
AU2012253422B2 (en) 2011-05-10 2015-08-13 Société des Produits Nestlé S.A. Methods of disease activity profiling for personalized therapy management
KR101851425B1 (ko) 2011-09-02 2018-04-23 네스텍 소시에테아노님 치료 효능 결정을 위한 신호 경로 단백질의 프로파일링
MX352274B (es) 2011-10-21 2017-11-16 Nestec Sa Metodos para mejorar el diagnostico de enfermedad inflamatoria intestinal.
SG11201405273YA (en) 2012-02-29 2014-09-26 Gilead Biologics Inc Antibodies to matrix metalloproteinase 9
ES2638971T3 (es) 2012-10-05 2017-10-24 Nestec S.A. Métodos para predecir y monitorizar la cicatrización de la mucosa
US20140113306A1 (en) 2012-10-17 2014-04-24 Rutgers, The State University Of New Jersey Diagnostic and screening methods for inflammation
CN113156139A (zh) 2013-01-03 2021-07-23 梅索磅秤技术有限公司 测定实验对象组
US20140236166A1 (en) 2013-02-15 2014-08-21 The Board Of Trustees Of The Leland Stanford Junior University Biomarkers for distinguishing benign, pre-malignant, and malignant pancreatic cysts
WO2015110989A1 (en) 2014-01-23 2015-07-30 Nestec S.A. Biomarker panel for assessment of mucosal healing
JP6904905B2 (ja) 2014-12-24 2021-07-21 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗α４β７インテグリン抗体による治療の結果の予測
EP3247343A1 (en) 2015-01-23 2017-11-29 Nestec S.A. Nutritional composition useful in the treatment of ibd patients
MX2017010336A (es) 2015-02-26 2017-12-20 Genentech Inc Antagonistas de integrina beta7 y métodos para el tratamiento de la enfermedad de crohn.
CN111094984A (zh) 2017-05-31 2020-05-01 普罗米修斯生物科学公司 克罗恩氏病患者的粘膜愈合评估方法
WO2020117795A1 (en) 2018-12-04 2020-06-11 Prometheus Biosciences, Inc. Assessment and monitoring of mucosal healing in children and adults with crohn's disease

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110045476A1 (en) * 2009-04-14 2011-02-24 Prometheus Laboratories Inc. Inflammatory bowel disease prognostics

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
吴小平等: "炎症肠炎病非侵入性标志物研究进展", 《国际消化病杂志》 *
张静等: "炎性肠炎病血清学标志物研究进展", 《华北国防医药》 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105190314A (zh) * 2013-01-21 2015-12-23 阿布维公司 用于炎性疾病的抗-tnf和抗-il17联合疗法生物标志物
CN109998488A (zh) * 2019-04-13 2019-07-12 中国医学科学院北京协和医院 克罗恩病和肠道溃疡型淋巴瘤的鉴别模型及构建方法
CN114859060A (zh) * 2022-05-06 2022-08-05 广州市胸科医院 一种细胞因子组及其应用
CN114859060B (zh) * 2022-05-06 2025-01-28 广州市胸科医院 一种细胞因子组及其应用

Also Published As

Publication number Publication date
WO2012154987A1 (en) 2012-11-15
US10086072B2 (en) 2018-10-02
US11160863B2 (en) 2021-11-02
CA2839792A1 (en) 2012-11-15
US20220096629A1 (en) 2022-03-31
US12485171B2 (en) 2025-12-02
RU2013154566A (ru) 2015-06-20
IL229120B (en) 2018-05-31
NZ711144A (en) 2017-01-27
AU2012253422A1 (en) 2013-05-02
EP2707504A1 (en) 2014-03-19
MX2018008324A (es) 2021-11-16
JP2018072349A (ja) 2018-05-10
AU2012253422B2 (en) 2015-08-13
US20140141983A1 (en) 2014-05-22
MX2013013096A (es) 2014-07-14
JP2014517279A (ja) 2014-07-17
ZA201309258B (en) 2016-08-31
CN110544517A (zh) 2019-12-06
SG194710A1 (en) 2013-12-30
MX362132B (es) 2019-01-07
BR112013028808A2 (pt) 2016-09-06
KR20140032424A (ko) 2014-03-14
NZ617009A (en) 2015-09-25
IL229120A0 (en) 2013-12-31
US20190060449A1 (en) 2019-02-28
JP2020098213A (ja) 2020-06-25

Similar Documents

Publication Publication Date Title
US12485171B2 (en) Methods of disease activity profiling for personalized therapy management
CN103299190B (zh) 确定抗药物抗体同种型的方法
CN103502815B (zh) 检测针对抗-TNFα药物的自身抗体的测定法
EP2904405B1 (en) Methods for predicting and monitoring mucosal healing
HK40017436A (en) Methods of disease activity profiling for personalized therapy management
NZ617009B2 (en) Methods of disease activity profiling for personalized therapy management
NZ711144B2 (en) Methods of disease activity profiling for personalized therapy management

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20190704

Address after: Vevey

Applicant after: SOCIETE DES PRODUITS NESTLE S. A.

Address before: Vevey

Applicant before: Nestle Products Technical Assistance Co., Ltd.

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20140319